SecBot SecBot

SILO

Silo Pharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001514183 Biotech & Drug Discovery
$1.16 −0.02 (−1.69%)
Oct 26 4:00 PM ET · prev $1.18
Market cap
$2.2M
Nano cap
1 year
−85.9%
from $8.23 · Oct 28
30 days
−29.7%
from $1.65
52-week range
$1.13–9.99
−88% from high · low Oct 19
Avg volume 20D
102.9K
Oct 2 spike 1.15M
Short interest
22.1K
≈1.2% of shares · −36.7%
Days to cover
1.0
at average volume
Filing reports
8
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4
Strongest BULLISH Silo Pharma announced that the USPTO has issued a Notice of Allowance for a patent covering its lead asset…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersCOVERING

    Short interest −36.7% to 22.1K shares. 1.0 days to cover, ≈1.2% of shares.

  • TrendDOWNTREND

    39% below its 50-day average.

Who's buying

13F
Top holderSharesValue
CITADEL ADVISORS LLC16,800$104.3K
VANGUARD CAPITAL MANAGEMENT LLC11,956$74.2K
VANGUARD FIDUCIARY TRUST CO874$5.4K
CITIGROUP INC1$6.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Aug 2023
Recent actions
DateFirmActionRating
Aug 28, 2023Laidlaw & Co.
INITIATE
INITIATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Silo Pharma acquired software and IP assets marketed as 'Reputation Endpoints' from Larry King in exchange for 150,000…
8-K — Impact 3/10
Oct 2, 2026 SEC
Silo Pharma acquired software, technology, and related intellectual property (the 'Klone' brand web-based tools) from…
8-K — Impact 4/10
Sep 30, 2026 Other
Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models
Sep 18, 2026 Press
Silo Pharma announced that the USPTO has issued a Notice of Allowance for a patent covering its lead asset SPC-15, an…
Impact 5/10
Aug 7, 2026 SEC
Silo Pharma's S-3 shelf registration statement became effective on August 6, 2026, allowing the company to sell…
EFFECT — Impact 4/10
Jul 14, 2026 Press
Silo Pharma announced via press release that its wholly owned AI-agent subsidiary, QwikAgents, has been accepted into…
Impact 4/10

Short side

FINRA· Oct 15, 2026
22,078
shares short
-36.7%
vs prior settlement
1.0
days to cover
≈1.2%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Press release
Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software
Sep 18, 2026
Announcement
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses
Sep 9, 2026
Press release
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical…
Aug 11, 2026
Earnings date
SILO Q2 2026 Earnings Scheduled — 2026-08-11
Aug 10, 2026
Press release
Silo Pharma Granted European Patent Covering Novel PTSD Therapy
Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop

SecBot reports

8 filings · 4 press releases · 0 bullish · 2 bearish · 6 neutral
All SILO filing & press-release reports (12)